Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UK-369,003 Dose Ranging in LUTS/BPH
NCT00457457Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2007
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial of gisadenafil besylate in benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) (7 arms), sponsored by Pfizer. Primary endpoint: International Prostate Symptom Score at 12 weeks. Started May 2007; status: completed.
02
Drugs
gisadenafil besylate
03
Conditions
benign prostatic hyperplasia (BPH)erectile dysfunction (ED)
Beyond the preview
Go deeper on NCT00457457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00457457.